Hye Hyeon Eum
Overview
Explore the profile of Hye Hyeon Eum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1681
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim N, Park S, Jo A, Eum H, Kim H, Lee K, et al.
Elife
. 2024 Nov;
13.
PMID: 39514276
This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICIs). Recognizing that patients with advanced-stage NSCLC rarely qualify for...
2.
Shin G, Choi B, Eum H, Jo A, Kim N, Kang H, et al.
PLoS One
. 2024 Aug;
19(8):e0301562.
PMID: 39190696
Single-cell RNA sequencing (scRNA-seq) has emerged as a versatile tool in biology, enabling comprehensive genomic-level characterization of individual cells. Currently, most scRNA-seq methods generate barcoded cDNAs by capturing the polyA...
3.
Eum H, Jeong D, Kim N, Jo A, Na M, Kang H, et al.
Br J Cancer
. 2024 Feb;
130(8):1388-1401.
PMID: 38424167
Background: Immune checkpoint inhibitors unleash inhibitory signals on T cells conferred by tumors and surrounding stromal cells. Despite the clinical efficacy of checkpoint inhibitors, the lack of target expression and...
4.
Kwon J, Kang J, Jo A, Seo K, An D, Baykan M, et al.
Nat Biotechnol
. 2023 Feb;
41(11):1593-1605.
PMID: 36797491
Identification of optimal target antigens that distinguish cancer cells from normal surrounding tissue cells remains a key challenge in chimeric antigen receptor (CAR) cell therapy for tumors with intratumoral heterogeneity....
5.
Jo A, Jeong D, Eum H, Kim N, Na M, Kang H, et al.
Int J Cancer
. 2023 Jan;
152(9):1964-1976.
PMID: 36650700
Immune checkpoint inhibitors (ICIs) induce activation and expansion of cytotoxic T cells. To depict a comprehensive immune cell landscape reshaped by the CTLA-4 checkpoint inhibitor, we performed single-cell RNA sequencing...
6.
Kim N, Jeong D, Jo A, Eum H, Lee H
BMC Cancer
. 2022 Nov;
22(1):1186.
PMID: 36397035
Background: Single-cell RNA sequencing (scRNA-seq) enables the systemic assessment of intratumoral heterogeneity within tumor cell populations and in diverse stromal cells of the tumor microenvironment. Gain of treatment resistance during...
7.
Nguyen T, Jung S, Nguyen H, Lee B, Vu S, Myagmarjav D, et al.
J Hematol Oncol
. 2022 Jun;
15(1):82.
PMID: 35710446
Much higher risk of cancer has been found in diabetes patients. Insulin receptor (IR) and insulin-like growth factor 1 receptor (IGF1R) have been extensively studied in both breast cancer and...
8.
Ryu S, Shin H, Eum H, Park J, Choi W, Na H, et al.
Front Immunol
. 2022 Jan;
12:767037.
PMID: 35069539
Dendritic cells (DCs) are key antigen-presenting cells that prime naive T cells and initiate adaptive immunity. Although the genetic deficiency and transgenic overexpression of granulocyte macrophage-colony stimulating factor (GM-CSF) signaling...
9.
Kim N, Eum H, Lee H
Biomolecules
. 2021 Aug;
11(8).
PMID: 34439827
The ability of single-cell genomics to resolve cellular heterogeneity is highly appreciated in cancer and is being exploited for precision medicine. In the recent decade, we have witnessed the incorporation...
10.
Eum H, Kwon M, Ryu D, Jo A, Chung W, Kim N, et al.
Exp Mol Med
. 2020 Dec;
52(12):1976-1988.
PMID: 33277616
Gastric cancer (GC) patients develop malignant ascites as the disease progresses owing to peritoneal metastasis. GC patients with malignant ascites have a rapidly deteriorating clinical course with short survival following...